Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
The treatment, which patients will take using an inhaler, works by reducing the bacteria in the lungs that causes tuberculosis while also helping the patient’s immune system fight the disease.
There is only one vaccine for tuberculosis, developed in 1921. It is unreliable in preventing the most common form of TB, and is not suitable in all patient groups. The vaccine works best against specific forms of TB and is usually given to infants in at-risk populations.
Tuberculosis is one of the top 10 causes of death worldwide. The World Health Organization (WHO) data show that 10 million people fell ill with TB and 1.6 million died from the disease in 2017. WHO estimates that there were 558,000 new cases with resistance to the most effective first-line antibiotic. Of those resistant to the drug, 82% were resistant to multiple antibiotics.
Funded by the Health Research Board (HRB) and the Royal City of Dublin Hospital Trust, the research is published in the European Journal of Pharmaceutics & Biopharmaceutics.
The work, led by Dr Gemma O’Connor and Prof Sally-Ann Cryan in RCSI, was carried out in collaboration with research teams in St James Hospital, Trinity College Dublin and Imperial College London. Prof Joseph Keane and Dr Mary O’Sullivan led the team at St James Hospital and Trinity College Dublin with Dr Brian Robertson and Dr Nitya Krishnan leading the team at Imperial College London.
Multidrug-resistant TB (MDR-TB) is seen as both a public health crisis and a health security threat. Ending the TB epidemic by 2030 is listed among the health targets of the United Nations Sustainable Development Goals.
The pathogen that causes tuberculosis spreads by people breathing infected droplets into their lungs, where the disease can remain dormant or spread further. The research makes use of a derivative of Vitamin A called all trans retinoic acid, atRA, which previous studies have shown is an effective treatment for tuberculosis.
“Many cases of TB are now becoming resistant to existing antibiotics. This new treatment could be used alongside antibiotics to treat drug-resistant TB and also possibly reduce the rate of antibiotic resistance resulting from conventional antibiotic treatments,” said Prof Cryan, Associate Professor of Pharmaceutics in RCSI School of Pharmacy and the study’s senior author.
Using a spray-drying process, the researchers packaged atRA within safe-for-consumption particles that are small enough to use in an inhaler. These particles efficiently delivered the treatment and significantly reduced tuberculosis-causing bacteria and associated lung damage, which supports their potential for clinical testing.
“Unfortunately, tuberculosis remains a significant problem for world health. We urgently need innovative treatments like this one if we are to achieve the UN 2030 health targets,” said Prof Keane, Professor at Trinity College Dublin School of Medicine and Consultant Respiratory Physician in St James’s Hospital.
Learn more: RCSI researchers develop new tuberculosis treatment
The Latest on: Tuberculosis
[google_news title=”” keyword=”tuberculosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Tuberculosis
- The path to a better tuberculosis vaccine runs through Montanaon April 29, 2024 at 10:20 am
A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.
- Tuberculosis case in Corby school as health bosses begin screening 'close contacts'on April 29, 2024 at 7:36 am
A child at Brooke Weston Academy in Corby has received a diagnosis of tuberculosis. The illness is rarely seen in children in the UK and causes a persistent cough, a high temperature, weight loss, ...
- After steady decline, TB has increased every year since 2020 in U.S.on April 29, 2024 at 2:30 am
But the CDC report describes the incidence of TB in the United States as still “among the lowest in the world.” ...
- Harnessing immune enhancement to combat drug-resistant tuberculosison April 28, 2024 at 11:17 am
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- Enhancing Immunity to Combat Tuberculosison April 27, 2024 at 9:10 am
Researchers explore host-directed therapies, harnessing the body's immune system to combat tuberculosis, including drug-resistant strains.
- Experts develop immune-enhancing therapies to target tuberculosison April 26, 2024 at 3:10 pm
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- Revvity unveils a new era of automated tuberculosis testingon April 26, 2024 at 8:38 am
Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to ...
- A new hope for tuberculosis?on April 26, 2024 at 6:13 am
If we can say “COVID is still here,” then what of tuberculosis (TB), which has been around since time immemorial and has killed more Filipinos than the coronavirus, even during the ...
- She Died Of Tuberculosis During The New England Vampire Panic, But Her Family Believed She Was Haunting Her Sister, So They Dug Up Her Grave, Removed Her Heart, And Burned It ...on April 25, 2024 at 4:00 pm
At one point in time, Rhode Island was consumed with what we call a vampire panic today. Due to an outbreak of tuberculosis and the freaky symptoms the disease caused, many people believed that the ...
- Drug-resistant tuberculosis responds rapidly to bedaquiline-based second-line therapy, claims studyon April 25, 2024 at 8:31 am
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking ...
via Bing News